blog
Last updated: 2024-10-13

Treakisym Blood Cancer Drug Information

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Treakisym Blood Cancer Drug Information

Treakisym Blood Cancer Drug Information

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan
  • January 6, 2016
  • Reading time: 1 minute

Based on a December 24, 2015 press release from SymBio Pharmaceuticals, the manufacturer of Treakisym (bendamustine) — a drug for lymphoma — the company has submitted a regulatory application in Japan for Treakisym in blood cancers including chronic lymphocytic leukemia (CLL). Prior clinical trials enrolled patients with refractory intermediate- or high-grade non-Hodgkin lymphoma and previously untreated multiple myeloma patients.

Key Points from the Press Releases

  1. Application for approval of TREAKISYM for chronic lymphocytic leukemia (CLL)
  2. Application for first-line treatment use in low-grade non-Hodgkin lymphoma and mantle cell lymphoma
  3. For rare cancers, the company seeks to shorten the regulatory review period in Japan

Sources:

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Consult on LINE Contact an advisor
Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Reading

Public Television Talk Show - Part 2

A follow-up program on cancer immunotherapy from public television. Medical Supporter shares this program as a resource for patients interested in learning more about immunotherapy approaches.

2019-06-07

Small Cell Lung Cancer Information Part 2

Continued coverage of small cell lung cancer treatment approaches and clinical trials available in Japan. Medical Supporter helps international patients access important SCLC treatment information.

2019-11-01

Introduction to Cancer Stem Cell Inhibitor BBI608 (Napabucasin)

Overview of a Phase 3 clinical trial evaluating paclitaxel combined with BBI608 (napabucasin), a cancer stem cell inhibitor, in previously treated gastric cancer patients. The trial enrolled 680 participants across Japan, the United States, Australia, Russia, and Germany.

2016-03-15

Cancer Treatment Information

Clinical information, treatment updates, and patient resources for cancer care. Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and Ministry of Economy, Trade and Industry (B-066).

2025-06-09